CHIH-CHIEH CHANHawkes, Jason EJason EHawkesKrueger, James GJames GKrueger2023-09-112023-09-112018-052040-6223https://scholars.lib.ntu.edu.tw/handle/123456789/635345Plaque psoriasis is one of the most common autoimmune skin diseases and is characterized by erythematous, scaly plaques. Many highly effective, targeted therapies have been developed as a result of an improved understanding of the pathogenesis of psoriasis. Using agents that target the central interleukin (IL)-23/IL-17 immune axis, this once difficult-to-treat disease is now among the most effectively treated autoimmune diseases with major clinical improvements possible in around 90% of patients. In this article, we outline the immune mechanisms responsible for the development of psoriasis and provide an overview of the novel IL-23 antagonists being used to manage this chronic skin disease.enguselkumabinterleukin 17interleukin 23mirikizumabpsoriasisrisankizumabtildrakizumab[SDGs]SDG3journal article10.1177/2040622318759282297962402-s2.0-85046019865https://api.elsevier.com/content/abstract/scopus_id/85046019865